Despite Recent Setbacks At Pfizer, R&D Chief Is Optimistic About R&D Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Mikael Dolsten cites Pfizer's latest efforts to be more efficient, improve R&D productivity, and implement precision medicine as key to its rebound.
You may also be interested in...
Ziarco Picks Up Pfizer Assets, Series A Round
A former Pfizer VP used four of the pharma’s programs to secure private financing from an unlikely investor and got the pharma to buy into the new start-up. Now, he hopes to develop next generation treatments for inflammatory and allergic diseases.
R&D Restructurings Aim To Placate Investors While Pharma Waits For Results
In response to poor R&D productivity and declining revenue as drug patents expire, Big Pharma companies have shrunk drastically to keep shareholders happy while they try to retool moribund R&D strategies.
R&D Restructurings Aim To Placate Investors While Pharma Waits For Results
In response to poor R&D productivity and declining revenue as drug patents expire, Big Pharma companies have shrunk drastically to keep shareholders happy while they try to retool moribund R&D strategies.